Cargando…
Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 202...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855209/ https://www.ncbi.nlm.nih.gov/pubmed/35187075 http://dx.doi.org/10.3389/fmolb.2021.810251 |
_version_ | 1784653606765461504 |
---|---|
author | Xie, Qing-Yu Liu, Hai-Yan Guo, Ze-Yi Wu, Yan-Ping He, Guo-Lin Cai, Lei Pan, Ming-Xin Fu, Shun-Jun |
author_facet | Xie, Qing-Yu Liu, Hai-Yan Guo, Ze-Yi Wu, Yan-Ping He, Guo-Lin Cai, Lei Pan, Ming-Xin Fu, Shun-Jun |
author_sort | Xie, Qing-Yu |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 2020, he received two cycles of transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC-Folfox), sorafenib, and camrelizumab every 3 weeks. Due to the end of HAIC treatment, he underwent drug-eluting transcatheter arterial chemoembolization (dTACE) once, sorafenib, and camrelizumab. However, because of worsening liver function, we interrupted TACE and only gave sorafenib and camrelizumab in August 2020. Although he received systemic therapy, the tumors still rapidly progressed and we considered the possibility of tumor resistance. Subsequently, regorafenib was given. In September, the patient underwent conventional TACE (cTACE) once, regorafenib, and camrelizumab. After half a year of comprehensive treatment, the treatment effect was not satisfactory, and he returned to the local hospital to received regorafenib every day and camrelizumab once every 3 weeks. The patient found that the tumor and lung metastasis had shrunk significantly after 1 year of the initial diagnosis, then he was admitted to our hospital and received surgery treatment, and now he has survived disease-free for 6 months. |
format | Online Article Text |
id | pubmed-8855209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88552092022-02-19 Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy Xie, Qing-Yu Liu, Hai-Yan Guo, Ze-Yi Wu, Yan-Ping He, Guo-Lin Cai, Lei Pan, Ming-Xin Fu, Shun-Jun Front Mol Biosci Molecular Biosciences Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 2020, he received two cycles of transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC-Folfox), sorafenib, and camrelizumab every 3 weeks. Due to the end of HAIC treatment, he underwent drug-eluting transcatheter arterial chemoembolization (dTACE) once, sorafenib, and camrelizumab. However, because of worsening liver function, we interrupted TACE and only gave sorafenib and camrelizumab in August 2020. Although he received systemic therapy, the tumors still rapidly progressed and we considered the possibility of tumor resistance. Subsequently, regorafenib was given. In September, the patient underwent conventional TACE (cTACE) once, regorafenib, and camrelizumab. After half a year of comprehensive treatment, the treatment effect was not satisfactory, and he returned to the local hospital to received regorafenib every day and camrelizumab once every 3 weeks. The patient found that the tumor and lung metastasis had shrunk significantly after 1 year of the initial diagnosis, then he was admitted to our hospital and received surgery treatment, and now he has survived disease-free for 6 months. Frontiers Media S.A. 2022-02-04 /pmc/articles/PMC8855209/ /pubmed/35187075 http://dx.doi.org/10.3389/fmolb.2021.810251 Text en Copyright © 2022 Xie, Liu, Guo, Wu, He, Cai, Pan and Fu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Xie, Qing-Yu Liu, Hai-Yan Guo, Ze-Yi Wu, Yan-Ping He, Guo-Lin Cai, Lei Pan, Ming-Xin Fu, Shun-Jun Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy |
title | Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy |
title_full | Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy |
title_fullStr | Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy |
title_full_unstemmed | Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy |
title_short | Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy |
title_sort | case report: one-year delay in the effect of conversion surgery therapy for advanced hepatocellular carcinoma after systemic therapy |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855209/ https://www.ncbi.nlm.nih.gov/pubmed/35187075 http://dx.doi.org/10.3389/fmolb.2021.810251 |
work_keys_str_mv | AT xieqingyu casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy AT liuhaiyan casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy AT guozeyi casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy AT wuyanping casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy AT heguolin casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy AT cailei casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy AT panmingxin casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy AT fushunjun casereportoneyeardelayintheeffectofconversionsurgerytherapyforadvancedhepatocellularcarcinomaaftersystemictherapy |